Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 1-11

  Hnatyszyn, H James ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA; RECOMBINANT INTERFERON;

CHRONIC HEPATITIS; DISEASE COURSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS GENOME; VIRUS HEPATITIS; VIRUS LOAD; ALGORITHM; GENETICS; VIROLOGY;

ALGORITHMS; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT;

EID: 18344381087     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Ohno T & Lau JY. The 'gold-standard,' accuracy, and the current concepts: hepatitis C virus genotype and viremia. Hepatology 1996; 24:1312-1315.
2. Anderson JC, Simonetti J, Fisher DG, Williams J, Yamamura Y, Rodriguez N, Sullivan DG, Gretch DR, McMahon B & Williams KJ. Comparison of different HCV viral load and genotyping assays. Journal of Clinical Virology 2003; 28:27-37.
3. Bullock GC, Bruns DE & Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clinical Chemistry 2002; 48:2147-2154.
4. Zein NN. Clinical significance of hepatitis C virus genotypes. Clinical Microbiology Reviews 2000; 13:223-235.
5. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clinical Liver Disease 2003; 7:45-66.
6. Howard CR. Hepatitis C virus: clades and properties. Journal of Gastroenterology & Hepatology 2002; 17(Suppl):S468-470.
7. Geller SA. Hepatitis B and hepatitis C. Clinics in Liver Disease 2002; 6:317-334.
8. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM & Esteban JI. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321-1324.
9. Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, Holmes EC & Smith DB. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. Journal of General Virology 1996; 77(Pt 12):3013-3024.
10. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. Journal of Gastroenterology & Hepatology 2002; 17:643-650.
11. Furione M, Simoncini L, Gatti M, Baldanti F, Grazia Revello M & Gerna G. HCV genotyping by three methods: analysis of discordant results based on sequencing. Journal of Clinical Virology 1999; 13:121-130.
12. Widell A, Shev S, Mansson S, Zhang YY, Foberg U, Norkrans G, Fryden A, Weiland O, Kurkus J & Nordenfelt E. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. Journal of Medical Virology 1994; 44:272-279.
13. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y & Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. Journal of General Virology 1992; 73(Pt 3):673-679.
14. Haushofer AC, Berg J, Hauer R, Trubert-Exinger D, Stekel HG & Kessler HH. Genotyping of hepatitis C virus-comparison of three assays. Journal of Clinical Virology 2003; 27:276-285.
15. Comanor L, Elkin C, Leung K, Krajden M, Kronquist K, Nicolas K, Horansky E, deMedina M, Kittichai P, Sablon E, Ziermann R & Sherlock C. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. Journal of Clinical Virology 2003; 28:14-26.
16. Zheng X, Pang M, Chan A, Roberto A, Warner D & Yen-Lieberman B. Direct comparison of hepatitis C virus genotypes tested by INNO-LIPA HCV II and TRUGENE HCV genotyping methods. Journal of Clinical Virology 2003; 28:214-216.
17. Fujigaki H, Takemura M, Takahashi K, Yamada Y, Fujii H, Wada H, Saito K, Ohnishi H & Seishima M. Genotyping of hepatitis C virus by melting curve analysis with SYBR Green I. Annals of Clinical Biochemistry 2004; 41:130-132.
18. Dev AT, McCaw R, Sundararajan V, Bowden S & Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36:1259-1265.
19. Zoulim F, Chevallier M, Maynard M & Trepo C. Clinical consequences of hepatitis C virus infection. Reviews in Medical Virology 2003; 13:57-68.
20. Poynard T, Yuen MF, Ratziu V & Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-2100.
21. Flamm SL. Chronic hepatitis C virus infection. Journal of the American Medical Association 2003; 289:2413-2417.
22. Seeff LB & Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clinical Liver Disease 2003; 7:261-287.
23. Sannes LJ. Prospects for non-interferon based therapies to treat HCV infection. Spectrum - Therapy Markets & Emerging Technologies 2003:3/1-3/14.
24. Aizaki H, Saito A, Kusakawa I, Ashiwara Y, Nagamori S, Toda G, Suzuki T, Ishii K, Matsuura Y & Miyamura T. Mother-to-child transmission of a hepatitis C virus variant with an insertional mutation in its hypervariable region. Journal of Hepatology 1996; 25:608-613.
25. Balogun MA, Laurichesse H, Ramsay ME, Sellwood J, Westmoreland D, Paver WK, Pugh SF, Zuckerman M, Pillay D & Wreghitt T. Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. Communicable Diseases & Public Health 2003; 6:34-39.
26. Cavalheiro Nde P, Barone AA & Tengan FM. HCV serotypes in Brazilian patients. International Journal of Infectious Diseases 2002; 6:228-232.
27. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36:599-105.
28. Tengan FM, Eluf-Neto J, Cavalheiro NP & Barone AA. Sexual transmission of hepatitis C virus. Reviews in Institutional Medicine Tropical Sao Paulo 2001; 43:133-137.
29. Pekler VA, Robbins WA, Nyamathi A, Yashina TL, Leak B & Robins TA. Use of versant TMA and bDNA 3.0 assays to detect and quantify hepatitis C virus in semen. Journal of Clinical Laboratory Analysis 2003; 17:264-270.
30. Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M & Simmonds P. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Annals of Internal Medicine 1996; 124:868-876.
31. Szabo E, Lotz G, Paska C, Kiss A & Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathological Oncology Research 2003; 9:215-221.
32. Franco S, Gimenez-Barcons M, Puig-Basagoiti F, Furcic I, Sanchez-Tapias JM, Rodes J & Saiz JC. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. Journal of Medical Virology 2003; 71:195-204.
33. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:521-29.
34. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21:570-583.
35. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J & Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. Journal of General Virology 1993; 74(Pt 11):2391-2399.
36. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shin i T, Simmonds P, Smith D, Stuyver L & Weiner A. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Archives in Virology 1998; 143:2493-2503.
37. Bukh J, Miller RH & Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Seminars in Liver Disease 1995; 15:41-63.
38. Ohba K, Mizokami M, Ohno T, Suzuki K, Orito E, Ina Y, Lau JY & Gojobori T. Classification of hepatitis C virus into major types and subtypes based on molecular evolutionary analysis. Virus Research 1995; 36:201-214.
39. Tokita H, Okamoto H, Tsuda F, Song P, Nakata S, Chosa T, Iizuka H, Mishiro S, Miyakawa Y & Mayumi M. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proceedings of the National Academy of Sciences, USA 1994; 91:11022-11026.
40. Zein NN. The epidemiology and natural history of hepatitis C virus infection. Cleveland Clinic Journal of Medicine 2003; 70(Suppl 4):S2-6.
41. Pistello M, Maggi F, Vatteroni L, Cecconi N, Panicucci F, Bresci GP, Gambardella L, Taddei M, Bionda A & Tuoni M. Prevalence of hepatitis C virus genotypes in Italy. Journal of Clinical Microbiology 1994; 32:232-234.
42. Takada N, Takase S, Takada A & Date T. Differences in the hepatitis C virus genotypes in different countries. Journal of Hepatology 1993; 17:277-283.
43. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J & Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infections Diseases 1995; 171:1607-1610.
44. Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, Abo-Zeid M, Khalaf M, Miyakawa Y & Mizokami M. Exponential spread of hepatitis C virus genotype 4a in Egypt. Journal of Molecular Evolution 2004; 58:191-195.
45. Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, Tedder RS, Dusheiko GM, De Lamballerie X & Simmonds P. A genetic analysis of hepatitis C virus transmission between injection drug users. Journal of Infectious Diseases 2002; 186:1212-1221.
46. Chen YD, Liu MY, Yu WL, Li JQ, Dai Q, Zhou ZQ & Tisminetzky SG. Mix-infections with different genotypes of HCV and with HCV plus other hepatitis viruses in patients with hepatitis C in China. World Journal of Gastroenterology 2003; 9:984-992.
47. Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL & Simmonds P. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995; 345:1211-1213.
48. Bronowicki JP, Venard V, Botte C, Monhoven N, Gastin I, Chone L, Hudziak H, Rihn B, Delanoe C, LeFaou A, Bigard MA, Gaucher P & Rhin B. Patient-to-patient transmission of hepatitis C virus during colonoscopy. New England Journal of Medicine 1997; 337:237-240.
49. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T & Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Annals of Internal Medicine 1996; 125:634-639.
50. Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Jenkins GD & Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. Journal of Clinical Microbiology 2002; 40:495-500.
51. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clinical Liver Disease 2003; 7:127-137.
52. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL & Liang TJ. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. American Journal of Gastroenterology 1999; 94:1619-1626.
53. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM & Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53:420-424.
54. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ & Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39:119-124.
55. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R & Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. Journal of Hepatology 2001; 35:307.
56. Westin J, Nordlinder H, Lagging M, Norkrans G & Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. Journal of Hepatology 2002; 37:837-842.
57. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R & Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-1364.
58. Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, Schwartz J, Harrison E, Anderson M, Byrne T, Vargas HE, Douglas DD & Rakela J. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Digestive Disease Science 2004; 49:25-29.
59. Amoroso P, Rapicetta M, Tosti ME, Mele A, Spada E, Buonocore S, Lettieri G, Pierri P, Chionne P, Ciccaglione AR & Sagliocca L. Correlation between virus genotype and chronicity rate in acute hepatitis C. Journal of Hepatology 1998; 28:939-944.
60. Pozzato G, Moretti M, Croce LS, Sasso F, Kaneko S, Unoura M, Kobayashi K, Crovatto M, Santini G & Tiribelli C. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. Journal of Medical Virology 1995; 45:445-450.
61. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P & Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Annals of Internal Medicine 1995; 122:161-168.
62. Tanaka H, Tsukuma H, Yamano H, Okubo Y, Inoue A, Kasahara A & Hayashi N. Hepatitis C virus 1b(II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. Journal of Epidemiology 1998; 8:244-249.
63. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M & Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-758.
64. Murase J, Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Ikebe T & Kinoshita H. Correlation of clinicopathologic features of resected hepatocellular carcinoma with hepatitis C virus genotype. Japanese Journal of Cancer Research 1999; 90:1293-1300.
65. Ikeda K, Kobayashi M, Someya T, Saitoh S, Tsubota A, Akuta N, Suzuki F, Suzuki Y, Arase Y & Kumada H. Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002; 45:71-78.
66. Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA, Wendt NK, Mitchell PS, Germer JJ & Persing DH. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. American Journal of Gastroenterology 1996; 91:2560-2562.
67. Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW & Futagawa S. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surgery Today 2003; 33:421-425.
68. Di Martino V, Brenot C, Samuel D, Saurini F, Paradis V, Reynes M, Bismuth H & Feray C. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 2000; 70:1390-1396.
69. Widell A, Verbaan H, Wejstal R, Kaczynski J, Kidd-Ljunegren K & Wallerstedt S. Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes. Scandinavian Journal of Infectious Diseases 2000; 32:147-152.
70. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H & Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. Journal of Viral Hepatology 2000; 7:268-275.
71. Dutta U, Byth K, Kench J, Khan MH, Coverdale SA, Weltman M, Lin R, Liddle C & Farrell GC. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. Australian & New Zealand Journal of Medicine 1999; 29:300-307.
72. Naoumov NV, Chokshi S, Metivier E, Maertens G, Johnson PJ & Williams R. Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. Journal of Hepatology 1997; 27:331-336.
73. Su YH, Lu SL, Gu YH, Zhu TF & Zhu SN. In situ RT-PCR detection of hepatitis C virus genotypes in Chinese patients with hepatocellular carcinoma. Journal of Experimental Clinical Cancer Research 2002; 21:591-598.
74. Serra MA, Rodriguez F, del Olmo JA, Escudero A & Rodrigo JM. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. Journal of Viral Hepatitis 2003; 10:183-188.
75. Perez-Cano R, Fernandez-Gutierrez C, Lopez-Suarez A, Mira J & Giron-Gonzalez JA. Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus. Clinical Microbiolological Infections 2002; 8:589-597.
76. Charlton M. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection - unconvictable felon or wrongly accused? Liver Transplantation 2000; 6:243-245.
77. Saracco G, Olivero A, Ciancio A, Carenzi S & Rizzetto M. Therapy of chronic hepatitis C: a critical review. Current Drug Targets in Infectious Disorders 2003; 3:25-32.
78. Lipman MM & Cotler SJ. Antiviral therapy for hepatitis C. Current Treatment Options in Gastroenterology 2003; 6:445-453.
79. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S & Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 1998; 339:1485-1492.
80. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C & Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
81. McHutchison JG & Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clinical Liver Disease 2003; 7:149-161.
82. Liang TJ, Rehermann B, Seeff LB & Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine 2000; 132:296-305.
83. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD & Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
84. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A & Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004; 140:346-355.
85. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Annals of Internal Medicine 2004; 140:370-381.
86. Hadziyannis SJ & Papatheodoridis GV. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2003; 4:541-551.
87. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
88. Seeff LB & Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36:51-2.
89. Lyra AC, Ramrakhiani S, Bacon BR & Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. Journal of Clinical Gastroenterology 2004; 38:68-71.
90. Diago M, Hassanein T, Rodes J, Ackrill AM & Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Annals of Internal Medicine 2004; 140:72-73.
91. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC & Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. Journal of Infectious Diseases 2003; 187:1071-1074.
92. Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Current Opinion in Infectious Diseases 2003; 16:587-592.
93. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV & Thursz MR. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes & Immunity 2003; 4:411-419.
94. Polyak SJ, Khabar KS, Rezeiq M & Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. Journal of Virology 2001; 75:6209-6211.
95. Ezelle HJ, Balachandran S, Sicheri F, Polyak SJ & Barber GN. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A. Virology 2001; 281:124-137.
96. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N & Gretch DR. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. Journal of Virology 2001; 75:6095-6106.
97. Polyak SJ & Gerotto M. The molecular basis for responsiveness to anti-viral therapy in hepatitis C. Forum (Genova) 2000; 10:46-58.
98. Polyak SJ. Hepatitis C virus - cell interactions and their role in pathogenesis. Clinical Liver Disease 2003; 7:67-88.
99. Houghton M. Strategies & prospects for vaccination against the hepatitis C viruses. Current Topics in Microbiology & Immunology 2000; 242:327-339.
100. Arribillaga L, de Cerio AL, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J & Lasarte JJ. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002; 21:202-210.
101. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E & Rosen HR. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37:577-589.
102. Matsui M, Moriya O & Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003; 21:1629-1639.
103. Park SH, Yang SH, Lee CG, Youn JW, Chang J & Sung YC. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 2003; 21:4555-4564.
104. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC & Thomas DL. Cross-genotype immunity to hepatitis C virus. Journal of Virology 2004; 78:1575-1581.
105. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM & Walker CM. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659-662.